EGFR and neoplasm: Differences in certain pathways, such as TNF or ERBB (for liver hepatocellular carcinoma and prostate adenocarcinoma), EGFR or Wnt (for lung squamous cell carcinoma), JAK-STAT (for kidney renal clear cell carcinoma), NFkB (for breast invasive carcinoma) and TGFβ, mTOR or NFkB (for stomach adenocarcinoma) were noted between tumor and normal tissue.